endocrinology

Ascendis scores in phase 3 trial, a boost to endocrine portfolio

Ascendis Pharma has its eyes on an NDA application this year after checking off top endpoints in a phase 3 hypoparathyroidism trial of TransCon PTH.

Max Bayer Mar 14, 2022 11:15am

New phase 3 data paint fuller picture for Horizon's teprotumumab

Apr 26, 2019 2:05pm

Apitope preps Graves’ disease drug for phase 2

Apr 16, 2018 10:40am

Crinetics raises $63.5M for oral acromegaly therapy

Mar 14, 2018 9:10am